ReviewFrontiers in pharmacology2024
The combination therapy of oncolytic virotherapy.
Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Advances in oncolytic virus delivery strategies and challenges in clinical translation.Materials today. Bio · 2026Review
- BTK inhibition enhances immunovirotherapy in glioblastoma via tertiary lymphoid structure modulation.bioRxiv : the preprint server for biology · 2026Article
- Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies.Virology journal · 2026Review
- Oncolytic viruses and neoantigen vaccines: opportunities and challenges in priming antitumour immunity.The Lancet regional health. Europe · 2026Review
- Fire in an Icy Desert: Oncolytic Virotherapy for Pancreatic Adenocarcinoma.Pharmaceutics · 2026Review
- Bridging mechanism and clinic: unlocking the full potential of oncolytic virus-based immunotherapy.Molecular cancer · 2026Review
- Heat up and Destroy: Immunotherapy of "Cold" Tumors Using the Example of Glioblastoma.International journal of molecular sciences · 2026Review
- Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances.Clinical and experimental medicine · 2026Review
- Review
- Immunological Impact of Oncolytic Adenoviruses On Cancer Therapy: Clinical Insights.European journal of immunology · 2025Review
- A Type I IFN-Inducing Oncolytic Virus Improves NK Cell-Mediated Killing of Tumor Cells In Vitro Through Multiple Mechanisms.Viruses · 2025Article
- Investigating the potential of oncolytic viruses in the treatment of melanoma: where do we go from here?Skin health and disease · 2025Review
- The pivotal role of cytokines in liver disease pathogenesis and therapeutic potential.Frontiers in immunology · 2025Review
- A Novel Oncolytic Virus Formulation Based on Mesenchymal Stem Cell-Derived Vesicles for Tumor Therapy.Journal of Cancer · 2025Article
- Oncolytic Virus Therapy in a New Era of Immunotherapy, Enhanced by Combination with Existing Anticancer Therapies: Turn up the Heat!Journal of Cancer · 2025Review
- Oncolytic virus therapy in hepatocellular carcinoma.Oncology research · 2025Review
- Optimizing Oncolytic Virotherapy for Malignant Glioma: From Bench to Bedside.Cancer management and research · 2025Review
- Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas.Viruses · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.